Background. Bloodstream infection (BSI) to due vancomycin-resistant Enterococcus (VRE) is an important complication of hematologic malignancy. Determining when to use empiric anti-VRE antibiotic therapy in this population remains a clinical challenge.
Bloodstream infection (BSI) due to vancomycin-resistant Enterococcus (VRE) has emerged as a major infectious complication of treatment of hematologic malignancy and hematopoietic stem-cell transplantation (HSCT). It is associated with poor prognosis [1] [2] [3] and requires special treatment considerations. National guidelines for management of febrile neutropenia do not recommend routine empiric anti-VRE therapy but do advocate for strategies that tailor antibiotic selection to host and microbiological factors [4] . In the last decade, our understanding of these factors in the context of the gastrointestinal microbiome has increased. Because of potential drug toxicity and the development of resistance to oxazolidinones and cyclic lipopeptides [5] [6] [7] , careful stewardship of these agents is warranted. To guide rational use of these agents, we aimed to develop a clinical prediction score for VRE BSI based on previously described risk factors in patients with hematological malignancy undergoing induction chemotherapy or HSCT.
METHODS
Approval for the study was granted by the institutional review board of Intermountain Healthcare. A retrospective derivation cohort of consecutive adult patients with hematological malignancy undergoing either induction therapy or hematopoietic stem cell transplantation at a single center from 2006 through 2014 was identified. A subset of patients suspected of having BSI (BSI risk) was identified on the basis of blood cultures being performed. The first date blood cultures were drawn was defined as the BSI risk index date. We chose this method because it was a more universal signal for suspicion of BSI than fever or neutropenia, which do not coincide in all patients with BSI. Demographic and clinical data were abstracted from the electronic record.
During the study period, neutropenia prophylaxis consisted of levofloxacin (500 mg orally daily) and penicillin VK (500 mg orally daily) or cephalexin (500 mg orally daily) for penicillin allergy. A standardized order set was used for empiric treatment of febrile neutropenia. Imipenem-cilastin 500 mg every 6 hours was the first-line antibiotic throughout the study period, with cefepime and piperacillin-tazobactam used as alternate agents. Vancomycin was added empirically for pulmonary, skin, and soft tissue, line sources, and severe sepsis. Daptomycin 6 mg/kg every 24 hours began being used per clinician choice in 2006. The most common scenario for use was in patients with persistent fever after 72 hours on first-line antibiotics, although timing and duration were subject to significant practice variation. In 2008, universal VRE stool screening was adopted. Stools for all patients were submitted weekly for VRE cultures on bile esculin agar plates. Positive growth was subbed to BBL Campylobacter agar plates, where growth suggested VRE. Vancomycin resistance was confirmed using MicroScan (Siemens). After VRE screening was instituted, both daptomycin use and rates of daptomycin nonsusceptible Enterococcus faecium infections increased. In 2011, daptomycin dosing was increased to 10-12 mg/kg every 24 hours.
VRE BSI was defined as any positive blood culture for Enterococcus species with resistance to vancomycin. Blood cultures were processed using the Phoenix automated system. Severe neutropenia was defined as absolute neutrophil count <100. Gastrointestinal disruption was defined as any of the following: severe mucositis, intestinal graft-versus-host disease, Clostridium difficile infection, using a surrogate of >3 stools/day. Renal insufficiency was defined as creatinine clearance of <30. Antianaerobic antibiotics were defined as metronidazole, clindamycin, ampicillin-sulbactam, amoxicillin-clavulanate, piperacillin-tazobactam, and ticarcillin-clavulanate. Carbapenems, including ertapenem, imipenem-cilastin, and meropenem, were classified separately. Daptomycin and linezolid comprised the anti-VRE antibiotic group.
Candidate risk factors reproducibly associated with VRE BSI in previous studies were selected a priori for analysis. Univariate analysis of categorical variables was performed using χ2 or Fisher's exact test, and continuous variables were analyzed using the Mann-Whitney U test for nonparametrically distributed data. P < .05 was considered significant, and all analyses were 2-tailed. Selection of candidate variables for multivariable analysis and inclusion in the prediction model was based on biological plausibility and significance at the P < .20 level in univariate analysis. The 95% confidence intervals for proportions and significance of differences between proportions were calculated by Z test and with the modified Wilson method [8] (Vassarstats.net, Poughkeepsie, NY). Binary logistic regression was used to evaluate effect of VRE BSI on mortality, and a linear regression model was similarly used to evaluate impact of VRE BSI on length of stay. A binomial logistic regression model with VRE BSI as the dependent variable was fitted with a minimal sufficient set of variables identified per above. Goodness of fit was confirmed using the Hosmer-Lemeshow calculation. Test performance characteristics including area under the receiver operator curve (AUROC) were computed using standard methods. SPSS Statistics for Windows, version 22.0 (IBM Corp, Armonk, NY) was used for statistical analysis.
A clinical prediction score was derived by sequential inclusion of risk factors significant in the regression model, with evaluation of test performance characteristics (sensitivity, specificity, and AUROC) after each addition. Probabilistic models were first evaluated, weighting risk factors according to regression ß-coefficient as well as cumulative models. Performance at each scoring level was evaluated for putative models until a candidate model and optimal cut point were identified.
Because risk of VRE BSI is a dynamic characteristic that varies over time based on fluctuating clinical characteristics, we then performed a time-series evaluation of the model's predictive ability for daily risk of VRE BSI in patients suspected of BSI. Clinical data were gathered for all BSI risk inpatient days from the index date forward for each admission. Time-variant data, such as absolute neutrophil count, renal function, VRE colonization, and stool count, were collected for each day. For each day, we included a flag indicating whether each antibiotic had been administered in any previous inpatient day. Using these data, the prediction score was then calculated for each inpatient BSI risk day. Antibiotic exposure to each class was counted if the patient had received an antibiotic prior to the inpatient date being calculated. Test performance characteristics and AUROC were calculated from this cohort. Posterior probability of VRE BSI at each cut point was determined by applying the positive likelihood ratio to a Bayesian nomogram. Relative increase in per diem probability was calculated for each level by dividing the probability at each scoring level by the baseline probability (incidence per day).
To explore the effect of anti-VRE antibiotic therapy on risk of VRE BSI, we reviewed all cases in which anti-VRE therapy was prescribed. For cases in which a VRE BSI occurred, we determined whether anti-VRE therapy had been given before or after the positive blood culture. We censored the data to include only cases in which antecedent anti-VRE therapy could have potentially affected whether VRE BSI occurred. We then looked at the effect of anti-VRE on VRE BSI in univariate analysis using the χ 2 test. We then further investigated this effect by forcing anti-VRE antibiotic therapy into the final multivariable VRE BSI regression.
RESULTS
The final cohort included 650 unique patients comprising 664 admissions, of which 230 were for leukemia induction, 230 were for autologous HSCT, and 204 were for allogeneic HSCT. Fourteen patients were included more than once if they were admitted for leukemia induction and later again for HSCT. Demographic data and clinical details are displayed in Table 1 . Acute myeloid leukemia (41.3%) was the most common underlying condition, followed by multiple myeloma (16.3%), non-Hodgkin's lymphoma (14.8%), and acute lymphoblastic leukemia (8.7%). Among HSCT recipients, haploidentical (9.8%) and cord blood (2.0%) were less common than matched donor status. Graft-versus-host disease of any grade was present in 54.9% of allogeneic HSCT. Overall 41.3% of patients had documented VRE colonization on weekly screening stool culture. Colonization was most common in allogeneic HSCT (53.9%), for which length of stay was also longest (median = 37 days). Anti-VRE antibiotics were received by 31.9% of patients, corresponding to 2041 days of anti-VRE therapy. Vancomycinresistant Enterococcus BSI occurred in 6.5% of admissions, ranging from 3.9% in autologous HSCT to 7.4% in acute leukemia and 8.3% in allogeneic HSCT. This corresponded to an incidence of 2.6 VRE BSI per 1000 BSI risk days. Nearly all BSI occurred in the setting of severe neutropenia (median absolute neutrophil count = 0; interquartile interval [IQI] = 0-0). Median days of severe neutropenia was 8.5, and in all subgroups most VRE BSI occurred just prior to neutrophil recovery near the maximum duration of severe neutropenia.
One-year mortality was higher in patients with VRE BSI (46.5% vs 31.8%; P = .046). This difference persisted after adjusting for age, date of admission, sex, and treatment type (leukemia induction, autologous HSCT, and allogeneic HSCT) (aOR 1.95; P = .04). However, 30-day mortality was not significantly different (4.6% vs 8.1%; P = .42). Length of stay was also significantly higher in admissions with VRE BSI (28 days [IQI = 20-36] vs 36 days [IQI = 26.25-50]; P < .0001). VRE BSI remained associated with increased length of stay after adjusting for age, date of admission, sex, and treatment type (unstandardized coefficient = 9.5; 95% confidence interval [CI] = 4.8-14.1; P < .0001).
The following variables were considered for inclusion in the regression models based on univariate analysis (see Supplementary Table 1) : acute myeloid leukemia, VRE colonization, severe neutropenia, gastrointestinal disruption, renal insufficiency, and prior exposure to any of the following antimicrobial classes during the hospital admission: 3rd-or 4 th -generation cephalosporins, aminoglycosides, carbapenems, vancomycin, antianaerobic agents. Number of prior days of carbapenem and antianaerobic treatment were also significant. In the logistic regression model, VRE colonization (aOR = 8.4; 95% CI = 3.4-20.6; P < .0001), renal insufficiency (creatinine clearance < 30; aOR = 2.4; 95% CI = 1.0-5.8; P = .046), aminoglycoside use (aOR = 4.7; 95% CI = 2.2-9.8; P < .0001), and antianaerobic antibiotic use (aOR = 2.8; 95% CI = 1.3-5.8; P = .007) correlated most closely with VRE BSI. In univariate analysis, anti-VRE therapy was not significantly associated with VRE BSI. In the multivariable model, however, anti-VRE therapy was associated with decreased odds of VRE BSI (aOR = 0.282; P = .004). In the predictive model that optimized sensitivity and specificity, VRE colonization was assigned greater weight (2 points) than 7 other equally weighted risk factors (see Table 2 ). Inclusion of carbapenem use, cephalosporin use, gastrointestinal disruption, and neutropenia resulted in optimal performance of the model. Modifying the model to include number of days of antibiotic exposure marginally increased the sensitivity. The VRE score effectively stratified risk of BSI, demonstrated by an AUROC of 0.84 (95% CI = .79-.89) (see Figure 1 ). This was higher than using colonization alone (AUROC = 0.73; 95% CI = .66-.80). The VRE score best differentiated low versus high risk of BSI at a threshold of ≥5 points with a sensitivity of 0.77 and specificity of 0.79 (see Table 3 ).
When the likelihood ratios of the score were applied to a Bayesian nomogram, the posterior probability of VRE BSI on days in which the score was ≥5 was increased 3.7-fold from baseline (pretest probability = 0.26%; post-test = 0.99%; absolute difference = 0.72 percentage points; 95% CI = .55-.90; absolute difference = 12.7 percentage points, 95% CI = 11.8-13.7; P < .0002). Expected inadequate therapy (undertreatment when VRE present) was similar with both strategies: VRE score (0.07%) compared with colonization status (0.06%; P = not significant). We also explored how adding prior anti-VRE therapy as a negative predictor with a value of −1 affected the prediction score. By applying this modified score to 16 233 BSI risk patient days, the model was less able to discriminate risk of VRE BSI with reduced sensitivity at a cut point of 5 (0.60 vs 0.77), and decreased specificity at a cut point of 4 (0.69 vs 0.79).
DISCUSSION
This study represents one of the largest single-institution experiences of VRE BSI in patients with hematological malignancies. In general, our findings align with observations reported in previous series and further solidify our understanding of the clinical characteristics of this important disease state. Like other studies [1-3, 9], we observed a disproportionate increase in mortality in patients with VRE BSI. Although we could not control for all possible confounders, this effect persisted after adjusting for leukemia, autologous HCT, and allogeneic HSCT. Interestingly, this effect was not seen for 30-day mortality, which suggests that VRE BSI may be a surrogate marker for other confluent factors portending poorer prognosis, as has been hypothesized [10] . In our cohort, VRE BSI occurred later in the induction or transplant course than other BSI, corresponding to the range of 10-18 days reported in other studies [3, [10] [11] [12] [13] [14] [15] . We observed that in many cases this occurred near the time of neutrophil recovery. However, whether this is related to increased capillary permeability or mucosal injury during immune reconstitution or simply coincides with the maximum duration of neutropenia needed before a host becomes vulnerable to infection with relatively low-virulence bacteria is unclear. Although our observed colonization rate was similar to reported rates in several centers [3, 16] , it was generally higher than most published rates in HSCT populations [2, [17] [18] [19] . Interestingly, the colonization-to-BSI ratio in these studies falls consistently within the narrow range of 3.2-3.7 to 1 [2, 3, 18, 19] . In our cohort (colonization/BSI ratio = 6.4), and in several others [16, 17, 20] , colonization was many-fold more common than was VRE BSI. This has important treatment implications if colonization status is used to guide therapy. Although this is a rational strategy, when colonization rates exceed BSI incidence, rates of unnecessary anti-VRE antibiotic use become unacceptably high. In our center, anti-VRE therapy was used in 31.9% of admissions, despite a per-admission rate of VRE BSI of only 6.5%. Nevertheless, unnecessary use of these agents leads to selective pressure for antibiotic resistance. This was the case at our institution, where daptomycin usage and daptomycin-nonsusceptible VRE rates trended inversely until 2011, when 33% of VRE isolates recovered were daptomycin resistant.
It is possible that the observed rate of VRE BSI was actually reduced due to the widespread empiric use of anti-VRE antibiotics in this cohort. In fact, when anti-VRE therapy, censored to only include administration preceding BSI in the event group, was included in a multivariable logistic regression model, it was significantly associated with reduced risk for VRE BSI. This observation has been reported previously [21] . This is of particular interest because it suggests that empiric anti-VRE therapy may actually prevent ultimate VRE BSI infection. This, in turn, highlights the need for more rational methods of selecting empiric anti-VRE antibiotics to optimize this benefit but minimize the development of resistance.
To this end, we propose strategies that apply principles of the precision medicine approach in which individual host risk factors are used to predict which patients are at high risk of progressing from VRE colonization to BSI [13, 22] . A notably conserved set of risk factors for VRE BSI has now emerged in patients with hematological malignancy: [1, 22, 23, 25, 28] , and T-cell depletion or human leukocyte antigen mismatch [13, 17, 20, 25] . The risk factors associated with VRE BSI identified in our cohort align closely with these data and further solidify the following pathophysiological model of VRE BSI during HSCT or induction therapy. First, patients are exposed to VRE, typically in the nosocomial environment [29] , and become colonized in the gastrointestinal tract (see Figure 3) . After colonization, antibiotic pressure exerts a dual effect; exposure to vancomycin selectively favors survival of VRE, whereas use of broad-spectrum agents, particularly those with antianaerobic spectrum, reduces the protective diversity of the host gastrointestinal microbiome. This antibiotic-mediated intestinal dysbiosis alters immune-microbiota surveillance and downregulates secretion of antimicrobial peptides that limit pathological overgrowth of VRE [30, 31] . In this context, VRE dominates the intestinal microbial ecosystem [32] . The innate and mucosal-associated immune barrier is then ablated by conditioning or induction regimens, which also compromise the integrity of the gastrointestinal mucosal barrier. This physical barrier is also frequently damaged by concomitant Clostridium difficile infection or graft-versus-host disease. This confluence of factors culminates in translocation of VRE into the bloodstream. These effects are likely magnified in hosts with advanced age and comorbidities such as renal insufficiency.
The VRE BSI prediction score is derived from host factors that have been reproducibly identified and that closely align with a plausible pathophysiological model of disease, supporting content validity. Performance characteristics suggest that the score effectively stratifies risk for VRE BSI with accumulating risk factors, allowing clinicians to make informed decisions about the risks versus rewards of starting empiric anti-VRE therapy. Although the risk of VRE BSI on any given day is low, at a cut point of ≥5, the score increased the posterior probability of VRE BSI almost 4-fold over baseline. The increased specificity of the score suggests potential to reduce unnecessary use of anti-VRE agents.
This study has several important limitations. First, the retrospective study design introduces potential bias due to unmeasured variables. Second, there are significant methodological challenges inherent to measuring factors that vary over time with respect to an event that only occurs in one group of patients, such as days of neutropenia with respect to BSI. Advanced machine learning methods such as Bayesian networks are needed to accurately model these multidimensional effects; this advanced analysis was beyond the scope of this report. However, although the score was originally modeled on static factors, we used a secondary temporally dynamic derivation by evaluating the score's performance in thousands of actual BSI risk inpatient days. Although this methodology mirrors clinical decision making, it cannot compare with prospective validation in accuracy. Independent, prospective validation in distinct populations will be necessary before the clinical utility and generalizability of the score can be established. 
